Contemporary management of actinic keratosis Editorial

Authors: Navarrete-Dechent, C.; Marghoob, A. A.; Marchetti, M. A.
Title: Contemporary management of actinic keratosis
Abstract: Actinic keratosis (AK) is a skin lesion characterized by itraepithelial keratinocyte dysplasia and molecular alterations shared with normal chronically sun-damaged skin and squamous cell carcinoma (SCC). AK can undergo spontaneous regression, stable existence, or malignant transformation to cutaneous SCC with progression rates to SCC ranging from 0% to 0.5% per lesion-year and AK spontaneous regression of 15–63%. As AK is a potential precursor of invasive SCC, it is commonly treated to mitigate the risk of malignant progression, including metastasis and death. There is a myriad of available spots (e.g. cryotherapy) and field (e.g. 5-fluorouracil, imiquimod photodynamic therapy) treatments for AK. Recently published randomized clinical trials have helped bridge the gap on AK management. In this viewpoint, we sought to summarize the most up-to-date evidence in the management of AK. © 2019 Taylor & Francis Group, LLC.
Keywords: squamous cell carcinoma; treatment; actinic keratosis; randomized controlled trial; skin cancer; non-melanoma skin cancer; evidence; keratinocyte carcinoma; number needed to treat
Journal Title: Journal of Dermatological Treatment
Volume: 32
Issue: 5
ISSN: 0954-6634
Publisher: Taylor & Francis Group  
Date Published: 2021-01-01
Start Page: 572
End Page: 574
Language: English
DOI: 10.1080/09546634.2019.1682504
PUBMED: 31621454
PROVIDER: scopus
Notes: Article -- Export Date: 2 August 2021 -- Source: Scopus
Citation Impact
MSK Authors
  1. Ashfaq A Marghoob
    507 Marghoob
  2. Michael Armando Marchetti
    149 Marchetti